R M Gulick

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
    R M Gulick
    Department of Medicine, New York University School of Medicine, New York, USA
    JAMA 280:35-41. 1998
  2. ncbi 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
    R M Gulick
    Weill Medical College of Cornell University, New York, New York, USA
    Ann Intern Med 133:35-9. 2000
  3. ncbi The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
    J J Eron
    Department of Medicine, Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599 7030, USA
    J Infect Dis 181:1622-8. 2000
  4. ncbi Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359
    R M Gulick
    Cornell Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Dept of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 182:1375-84. 2000
  5. ncbi Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373
    R M Gulick
    Weill Medical College of Cornell University and New York University School of Medicine, Cornell Clinical Trials Unit, New York, NY 10021, USA
    J Infect Dis 183:715-21. 2001
  6. ncbi Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease
    B H Lerner
    Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Ann Intern Med 129:573-8. 1998
  7. ncbi New antiretroviral drugs
    R M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10024, USA
    Clin Microbiol Infect 9:186-93. 2003

Detail Information

Publications7

  1. ncbi Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
    R M Gulick
    Department of Medicine, New York University School of Medicine, New York, USA
    JAMA 280:35-41. 1998
    ..Combination antiretroviral therapy can markedly suppress human immunodeficiency virus (HIV) replication but the duration of HIV suppression varies among patients...
  2. ncbi 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
    R M Gulick
    Weill Medical College of Cornell University, New York, New York, USA
    Ann Intern Med 133:35-9. 2000
    ..Antiretroviral regimens containing HIV protease inhibitors suppress viremia in HIV-infected patients, but the durability of this effect is not known...
  3. ncbi The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
    J J Eron
    Department of Medicine, Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599 7030, USA
    J Infect Dis 181:1622-8. 2000
    ..Persistent replication of HIV in the genital tract may have implications for the selection of resistant virus and sexual transmission of HIV-1...
  4. ncbi Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359
    R M Gulick
    Cornell Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Dept of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 182:1375-84. 2000
    ..18%; P=.002). Overall, one-third of patients who experienced virologic failure on an indinavir-containing regimen suppressed virus load levels while they were taking a new salvage regimen...
  5. ncbi Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373
    R M Gulick
    Weill Medical College of Cornell University and New York University School of Medicine, Cornell Clinical Trials Unit, New York, NY 10021, USA
    J Infect Dis 183:715-21. 2001
    ..7; P=.0012). In this study, most subjects who had taken amprenavir-based regimens and who changed to a 4-drug regimen achieved subsequent durable virologic suppression...
  6. ncbi Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease
    B H Lerner
    Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Ann Intern Med 129:573-8. 1998
    ..Encouraging the active participation of HIV-positive persons in their own treatment will help avoid judgmental and inaccurate assessments of patient behavior and may help patients take medications more successfully...
  7. ncbi New antiretroviral drugs
    R M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10024, USA
    Clin Microbiol Infect 9:186-93. 2003
    ..Investigational HIV integrase inhibitors include S-1360. Continued progress in the treatment of HIV disease will result from the development of new antiretroviral drugs...